T. I. Golikova

T. I. Golikova

Auto-generated profile, based on publicly available information

T. I. Golikova

Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2021 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
GMGeorgii Matveev
Georgii Matveev
TGT. I. Golikova
T. I. Golikova
АВА. А. Васильева
А. А. Васильева
EVE. V. Vasilieva
E. V. Vasilieva
ABAlina Yu Babenko
Alina Yu Babenko
ЕВЕ. Ю. Васильева
Е. Ю. Васильева
Background: Obesity is a global noncommunicable pandemic. The low effectiveness of treating obesity is associated with the difficulty of maintaining weight loss due to the reaction of the appetite regulation system. Drugs with central mechanisms of action can help overcome this problem.Aim: The aim of our study was to compare the effects of liraglutide and sibutramine (Reduxin) on the dynamics of weight and cardiometabolic parameters in obese patients without cardiovascular diseases.Materials and methods: We estimated the dynamics of the main metabolic parameters (BMI, glucose, lipid metabolism, blood pressure), the level of hormones involved in the regulation of fat metabolism (leptin, adiponectin, insulin), the ­HOMA-IR index, markers of oxidative stress and inflammation during therapy with liraglutide in comparison with reduxin for 6 months in obese patients.Results: 64 obese patients were included in the study: 25 patients — in the “Liraglutide” group, 39 patients — in the “Sibutramine” group in accordance with the declared inclusion / exclusion criteria. The included patients were young, average body mass index (BMI) (37.92 ± 5.45 kg / m2), average glycemic level was 5.47 ± 0.81 mmol /l, HOMA-IR was 6.01 ± 4.25, blood pressure was at inclusion was within the normal range, but 21.8% of patients received antihypertensive therapy.Both treatment options provided a comparable decrease in body weight (-10.28% vs -9.47%, p = 0.13)., Leptin level (-32.12% vs -41.77%, p = 0.77) and myeloperoxidase (-33.33% vs -19.91%, p = 0.2). The blood pressure level did not change significantly on liraglutide, while on reduxin the level of diastolic blood pressure (dBP) increased significantly (6.87%, p = 0.006). There was a more pronounced decrease in insulin levels compared to the baseline level (-46%, p = 0.005), as well as a decrease in the HOMA-IR index (-50.08, p = 0.005) on liraglutide therapy.An increase in adiponectin levels (+ 45.36% vs 14.01%, p = 0.0045) and a decrease in low density lipoprotein(LDL) cholesterol were significantly more pronounced on reduxin therapy (-15.03% vs -9.4%, p = 0.006).36% of the participants completed their participation in the study ahead of schedule due to the lack of effect in the form of weight loss in the «Liraglutide» group. Side effects in the “Liraglutide” group were observed in 16% of patients. 48% of patients took part in the study within 6 months. In the «Sibutramine» group 33.4% of patients completed the study ahead of schedule for reasons unrelated to the drug intake, the side effects were observed in 20.5% of patients. 46.1% of participants in the «Sibutramine» group received therapy for 6 months.Conclusions: This study confirms the previous findings that both liraglutide and reduxin therapy provide effective weight loss. We found a positive trend in markers of inflammation, atherogenesis and oxidative stress, and leptin levels. Liraglutide therapy was accompanied by a more pronounced effect on the state of carbohydrate metabolism, and reduxin therapy provided a more pronounced dynamics of lipid disorders and adiponexin. Both groups were characterized by a rather low adherence to therapy, but the incidence of side effects requiring stopping therapy was higher in the Sibutramine group.

31 March 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
ABAlina Yu Babenko
Alina Yu Babenko
GMGeorgii Matveev
Georgii Matveev
TAT. I. Alekseenko
T. I. Alekseenko
IDIlia Derevitskii
Ilia Derevitskii
MKM. A. Kokina
M. A. Kokina
ESE. V. Shlyakhto
E. V. Shlyakhto
Взаимосвязи компонентов метаболического синдрома с уровнем гормонов, вовлеченных в регуляцию метаболизма жировой ткани

12 October 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ELE. A. Lyasnikova
E. A. Lyasnikova
GMGeorgii Matveev
Georgii Matveev
TGT. I. Golikova
T. I. Golikova
IDIlia Derevitskii
Ilia Derevitskii
AFA. V. Fedorov
A. V. Fedorov
ABAlina Yu Babenko
Alina Yu Babenko
Introduction. Association of left ventricular hypertrophy (LVH) in obesity and accompanying metabolic risks with adipokines levels at the different stage of heart failure (HF) is still debatable.The aim of study was to investigate the relationship of circulating adipokines levels with LVH in obese patients at preclinical stage of HF.Materials and methods. The study included 74 obese patients: 43% had no markers of LVH (stage A HF, group 1); 57% had LVH (stage B HF, group 2). Transthoracic echocardiography, laboratory assessment of N-terminal fragment of the brain natriuretic peptide, soluble suppression of tumorigenesis-2 (sST2), circulating leptin and adiponectin levels, homeostasis model assessment of insulin resistance (IR) (HOMA-IR) were done. Matched-pairs analysis was applied.Results. Negative correlations of LVH with leptin levels in group 1 (stage A HF) and with adiponectin levels in group 2 (stage B HF) were detected (all p < 0.05). Positive correlations of the sST2 / adiponectin ratio and HOMA-IR with the parameters of LVH were detected in group 2 (all p >< 0.05). Conclusion. The direction of the associations between circulating adipokines and LVH varies with the preclinical stage of HF. The data obtained may reflect a relationship between heart remodeling in response to molecular mechanisms of inflammation and IR in obese patients at the certain stage of cardiovascular continuum. Keywords: leptin, adiponectin, insulin resistance, HOMA-IR, inflammation, sST2, left ventricular hypertrophy>˂ 0.05). Positive correlations of the sST2 / adiponectin ratio and HOMA-IR with the parameters of LVH were detected in group 2 (all p ˂ 0.05).Conclusion. The direction of the associations between circulating adipokines and LVH varies with the preclinical stage of HF. The data obtained may reflect a relationship between heart remodeling in response to molecular mechanisms of inflammation and IR in obese patients at the certain stage of cardiovascular continuum.

25 June 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
GZG. G. Zasypkin
G. G. Zasypkin
TGT. I. Golikova
T. I. Golikova
GMGeorgii Matveev
Georgii Matveev
ABAlina Yu Babenko
Alina Yu Babenko
Влияние различных вес-снижающих препаратов на характеристики пищевого поведения